FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2350-2353 June 2, 2005 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by DeAngelis, L. M. Related Article by Rutkowski, S. Related Article by Stupp, R. Related Article by Hegi, M. E. PubMed Citation

To the Editor: In the report by Rutkowski et al. (March 10 issue)¹ regarding treatment of early childhood medulloblastoma with postoperative chemotherapy alone, 20 of 43 children under the age of three years (46.5 percent) had desmoplastic medulloblastoma, and these 20 children had a five-year progression-free survival rate of 85 percent. The desmoplastic variant is considered to be less aggressive than classic medulloblastoma and occurs mainly in adolescents and adults.^2,3 As far as we know, desmoplastic histologic features are not found in a large proportion of children who are younger than three years of age. Could the somewhat higher-than-expected proportion . . . [Full Text of this Article]

This article has been cited by other articles:

• Mirzoeva, O. K., Kawaguchi, T., Pieper, R. O. (2006). The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity.. Molecular Cancer Therapeutics 5: 2757-2766 [Abstract] [Full Text]